Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05789602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of BPI-460372 in Advanced Solid Tumor Patients

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 27, 2025 (before its estimated April 17, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting Primary endpoints revised (3) · Study sites: 4 to 11 · Start date changed from estimate of Apr 18, 2023 to Apr 24, 2023 · 2 morev2 Show 5 more changesShow less
    • Primary endpoints revised (3)
    • Study sites: 4 to 11
    • Start date changed from estimate of Apr 18, 2023 to Apr 24, 2023
    • Eligibility criteria shortened, about 1 word
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
Trial Details
NCT Number NCT05789602
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov